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OBJECTIVES: Nonalcoholic fatty liver disease (NAFLD) is considered as the hepatic manifestation of metabolic
syndrome. Insulin resistance (IR) is a key component of metabolic syndrome. The aim was to
determine the dietary composition, physical activity, and histologic severity between NAFLD
patients with and without metabolic syndrome.
METHODS: Ninety-one patients with NAFLD completed the Block Food Frequency Questionnaire and the
Paffenbarger Physical Activity Questionnaire. IR was assessed by the homeostasis model
assessment (HOMA) index. Metabolic syndrome was defined by the ATP III clinical definition.
Nonalcoholic steatohepatitis (NASH) Clinical Network Scoring System was used to determine the
histologic severity of NAFLD.
RESULTS: Thirty-one patients (34%) had metabolic syndrome. Patients with metabolic syndrome had a higher
HOMA index (7.66 vs 4.45, p = 0.04), and consumed more carbohydrates (51% vs 45%, p = 0.03)
and less fat (34% vs 40%, p = 0.01) compared with those without metabolic syndrome; total daily
calorie, protein consumption, and physical activity were similar between the two groups. Patients
with metabolic syndrome had higher scores for steatosis (2.0 ± 0.8 vs 1.37 ± 1, p = 0.02), NASH
activity (4.13 ± 1.4 vs 3.13 ± 1.7, p = 0.004), and global NASH score (5.9 ± 1.7 vs 4.4 ± 2.3, p =
0.0006) compared with those without metabolic syndrome. When controlled for other factors
including dietary composition and physical activity, the presence of metabolic syndrome was a
significant risk factor for global NASH severity in addition to HOMA index and female gender.
CONCLUSION: Metabolic syndrome in patients with NAFLD is associated with a diet containing more carbohydrate
and less fat and greater histologic severity. The role of a carbohydrate-restricted diet in decreasing
the risk for metabolic syndrome and histologic severity should be assessed in patients with NAFLD.
(Am J Gastroenterol 2006;101:2247–2253)
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is now recognized
as one of the most common forms of chronic liver disease
in developed countries with an estimated prevalence of 10–
24% in the general population (1, 2). Obesity, type 2 diabetes
mellitus (DM), and hyperlipidemia are common risk factors
for NAFLD. As can be seen from the recent National Health
and Nutrition Examination Survey (NHANES) data (1999–
2002), the proportion of the U.S. population that is overweight
or obese is on the rise, with 65.2% of the population being
overweight (body mass index [BMI] >25) and 30.1% being
obese (BMI >30) (3). With the increase in the prevalence of
obesity in the United States and the association of obesity and
NAFLD, the prevalence of NAFLD is expected to increase in
the United States.
NAFLD is considered to be the hepatic manifestation of
metabolic syndrome. Metabolic syndrome is also increas-
ing in prevalence in the United States. It has increased from
23.1% in the NHANES III (1988–1994) study (4) to 26.7%
in the recently published NHANES study (1999–2002) for
adults aged 20–70 yr (3). Metabolic syndrome increases with
age and is found more commonly in women.
Several recent studies have now shown that insulin resis-
tance (IR) is a major step in the pathogenesis of NAFLD
(5–9). It is also the pathogenic link underlying the metabolic
abnormalities that constitute the metabolic syndrome such as
obesity, diabetes, and dyslipidemia (10). Metabolic syndrome
can be induced by different environmental factors, including
dietary habits (11). Recent reports have shown that the ad-
verse cardiovascular risk profile seen as part of metabolic
syndrome is associated with a diet high in carbohydrate and
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low in unsaturated fat and also with decreased physical activ-
ity (5, 12, 13). A recent study also showed that patients with
NAFLD consuming a diet high in carbohydrates and low in
fat have greater odds of hepatic inflammation (14), suggest-
ing a link between diet and liver injury possibly mediated
through IR. There is no study to date that has assessed the
relationship among metabolic syndrome, dietary composi-
tion, physical activity, and histologic severity in patients with
NAFLD.
The aims of this study were to determine dietary com-
position and physical activity and their relationship to his-




This was a prospective study of predictors of histologic sever-
ity in patients with NAFLD. Patients who presented to the
Hepatology clinic at the University of Michigan Medical Cen-
ter from March 2003 to November 2004 were enrolled into
the study by the following inclusion criteria: Patients 12 yr or
older with clinically suspected NAFLD based on persistent
elevation in aminotransferase levels (>1.5 upper limit of nor-
mal on two or more occasions at least 3 months apart) and/or
radiologic evidence of fatty liver with no identified etiology
and alcohol consumption less than 40 g/wk. A liver biopsy
should have been performed within 1 yr of entry into the
study and liver biopsy slides should be available for review
before enrollment. Patients were excluded from the study for
the following reasons: Other causes of chronic liver diseases,
alcohol use more than 40 g/wk (5 drinks/wk or more) within
the past 3 months or a history of long-term alcohol abuse
or dependence in the past, use of medications reported to
cause steatosis (including amiodarone, steroids, tamoxifen,
valproic acid, methotrexate, IV tetracycline) within the past
3 months or greater than 6 months in the past 2 yr, weight
reduction surgery within 1 yr or jejuno-ileal bypass in the
past, weight loss medication or participation in weight loss
program in the past 3 months, evidence of hepatic decompen-
sation, HIV antibody positive, pregnancy, or breast feeding.
The protocol and consent form were approved by the Insti-
tutional Review Board of the institution. All patients signed
the consent form at the time of screening for the study.
Study Design
Clinical information regarding the patients’ medical and sur-
gical history as well as medications was recorded. Laboratory
parameters to exclude other causes of chronic liver diseases
were examined. All patients underwent anthropometric and
laboratory investigations. Measurement of the waist and hip
circumference, weight, height, BMI, and blood pressure was
performed. Laboratory testing for metabolic abnormalities
including fasting triglyceride, HDL, glucose, and insulin was
obtained. Measurement of IR was determined by the home-
ostasis model assessment (HOMA) index (HOMA index =
[(fasting insulin × fasting glucose/18)/22.5]) (15). A HOMA
index value of ≥2.0 was selected to define IR in this study
as this value is considered abnormal and indicative of de-
creased insulin sensitivity in normal range weight and obese
individuals (15, 16).
Liver biopsy slides were obtained and reviewed by a pathol-
ogist. Patients who were enrolled completed the Block Food
Frequency Questionnaire (FFQ 98) (17) and the Paffenbarger
Physical Activity Questionnaire (PAQ) (18). The presence of
metabolic syndrome was defined by the criteria proposed by
the Third Report of National Cholesterol Education Program
expert panel on detection, evaluation, and treatment of high
blood cholesterol in adults (ATP III criteria) (19) as patients
who have three or more of the following: (1) Central obe-
sity measured by waist circumference greater than 35 inches
in women and 40 inches in men, (2) blood pressure grea-
ter than or equal to 135/85 mmHg, (3) fasting glucose greater
than or equal to 110 mg/dL, (4) fasting triglyceride greater
than or equal to 150 mg/dL, and (5) HDL less than 50 mg/dL
in women and 40 mg/dL in men. Patients who were being
treated with antihypertensive, lipid lowering, and diabetic
medications were considered as having hypertension, hyper-
lipidemia, and DM, respectively.
NAFLD Histology
A single pathologist, blinded to the patients clinical history
and laboratory tests, reviewed the slides using the nonalco-
holic steatohepatitis (NASH) Clinical Network Scoring Sys-
tem by Kleiner and Brunt (20). In brief, the presence and
severity of steatosis (0–3), lobular inflammation (0–3), hep-
atocyte ballooning (0–2), and fibrosis (0–4) were scored.
NASH activity score (0–8) is the sum of steatosis, lobular
inflammation, and ballooning. Global NASH score (0–12) is
the sum of NASH activity score and fibrosis.
Dietary Composition, Physical Activity, and Alcohol
Consumption
The Block FFQ 98 is the most frequently used questionnaire
for metabolic and dietary intervention studies and it has been
used in mixed gender and multiethnic populations (17). It
is a validated, self-administered questionnaire with pictures
of standardized serving sizes to estimate the usual dietary
intake. The questionnaire was mailed to the patients to be
filled out at home and reviewed by the dietician at the time
of the study visit for completeness. The dietitians inquired if
the questionnaire reflected common foodstuffs participants
typically consumed, and if there were any omissions or foods
that were not addressed. The completed questionnaires were
sent to Block Dietary Data Systems in Berkeley for analysis.
The data provided information regarding total calories con-
sumed per day, percent of carbohydrate, protein, fat, sweets,
and alcohol consumption. The consumed fat was divided into
monounsaturated, polyunsaturated, and saturated fat. Fiber,
cholesterol, and mineral consumption were also measured.
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Paffenbarger PAQ is a well-validated questionnaire (18)
designed to assess leisure physical activity. The time frame
of recall can include activity during the preceding week and
year at the time of administration. Leisurely activity is divided
into light, moderately vigorous, and combination activities.
For example, light activity (5 kcal/min) includes golf, walk-
ing, gardening, carpentry, bowling, baseball, biking, boating,
dancing, and ice skating. Examples of moderately vigorous
activity (10 kcal/min) include swimming, tennis, squash, rac-
quetball, jogging, running, basketball, skiing, and ice hockey.
Examples of combined activity (7.5 kcal/min) include weight
lifting. Physical activities were ranked (kilocalorie expendi-
ture) by metabolic equivalent (MET) value. Using this infor-
mation the average kilocalories burned in a week was esti-
mated and used for analysis.
Skinner survey, a well-validated instrument that estimates
alcohol consumption throughout an individual’s lifetime, was
used to interview patients and determine the amount of alco-
hol consumed (21). The information obtained included the
style of drinking, type of alcoholic beverage, average and
maximum amount drank each time, and life events that may
have affected drinking patterns.
Statistical Analysis
Comparisons between those with and without metabolic syn-
drome were performed using paired t-test and χ2 analyses as
appropriate (continuous variables using a two-sample t-test
and categorical variables using χ2 test). Correlation between
histology and variables was analyzed by Pearson’s correlation
coefficient. Statistical analysis was performed using SAS 9.1
(SAS Institute Inc., Cary, NC).
RESULTS
Ninety-one patients with histologically confirmed NAFLD
were evaluated for this study. Baseline clinical, biochemi-
cal, and histological characteristics of these 91 patients are
shown in Table 1. Thirty-one (34%) patients met criteria for
metabolic syndrome; 75 patients (82%) had evidence of IR
defined as HOMA index ≥2.0. Diabetes, hypertension, and
hyperlipidemia were seen in 18 (19.8%), 43 (47.3%), and
49 (53.9%) patients, respectively. None of the patients had
weight loss surgery in the past. Overall, histologic disease
severity of NAFLD was mild with mean NASH activity, fi-
brosis, and global scores of 3.0, 1.5, and 4.9, respectively.
The mean total kilocalories consumed per day were 1,866
± 762.5 with the average proportion of dietary carbohydrate,
fat, and protein consumption of 47%, 38%, and 15%, respec-
tively. Men consumed an average of 1,984 ± 779 kcal/day
and women consumed 1,776 ± 745 kcal/day (p = 0.20). The
total amount of calories consumed tended to be lower in the
group of patients with metabolic syndrome. Analysis of the
daily average dietary macronutrient intake based on gender
showed that consumption of carbohydrate, fat, and protein
was 45%, 40%, and 15% of total daily intake among men and
49%, 37%, and 15% among women, respectively, in our study
(p = 0.64, 0.06, 0.28). The only dietary difference between
men and women was that men had a higher consumption of
saturated fat than women (27 g/day vs 21 g/day, p = 0.01).
Average leisurely physical activity was 1,325 kcal/wk with
no significant difference seen between men and women.
Table 1 compares the clinical, biochemical, and histo-
logical characteristics of NAFLD patients with and without
metabolic syndrome. There was no statistically significant
difference in gender distribution, BMI, ALT, and AST lev-
els between patients with and without metabolic syndrome.
As can be expected, patients with metabolic syndrome had
significantly greater mean waist circumference and waist-hip
ratio, lower HDL cholesterol, and higher triglyceride levels
compared with those without metabolic syndrome. In addi-
tion, patients with metabolic syndrome also had a greater
degree of IR.
Dietary Composition in NAFLD Subjects with and without
Metabolic Syndrome
Patients with metabolic syndrome had significantly higher
mean carbohydrate consumption (percent of calories, 51 ±
11 vs 45 ± 10, p = 0.03) than those without metabolic syn-
drome. In addition, the subjects with metabolic syndrome
also consumed less fat (percent of calories, 34 ± 10 vs 40 ±
8, p = 0.01). When the different types of fat consumption,
including saturated, polyunsaturated, and monounsaturated,
were examined, there was no significant difference between
the two groups. Although there was a tendency for those
without metabolic syndrome to consume more calories and
fiber (17.7 ± 9.4 vs 16.2 ± 6.9 g/day, p = 0.4), this was
not statistically significant. In addition, percent of calories
from protein did not differ between those with and without
metabolic syndrome (Fig. 1).
Physical Activity in NAFLD Subjects with and without
Metabolic Syndrome
Leisurely physical activity, measured as kilocalories per
week, did not significantly differ between patients with and
without metabolic syndrome. Using the median physical ac-
tivity value of 1,036 kcal/wk, patients were divided into
two groups. There was no difference in the waist circumfer-
ence, waist/hip ratio, HOMA, histologic severity of NAFLD,
or proportion with metabolic syndrome between these two
groups. However, BMI was lower in the group that exercised
more than 1,036 kcal/wk (34.7 ± 6.8 vs 31 ± 6.3, p = 0.01)
(Table 1).
NAFLD Histology in Subjects with and without Metabolic
Syndrome
Patients with metabolic syndrome had significantly higher
mean scores for steatosis (2.0 ± 0.8 vs 1.37 ± 1, p = 0.002),
NASH activity (4.13 ± 1.4 vs 3.13 ± 1.4, p = 0.004), and
global NASH scores (5.9 ± 1.7 vs 4.4 ± 2.3, p = 0.0006).
Although there was a trend toward a higher mean fibrosis
score in patients with metabolic syndrome (1.8 ± 1.3 vs 1.29
± 1.1), this was not statistically significant (Table 1).
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Table 1. Characteristics of NAFLD Patients with and without Metabolic Syndrome
All Patients Metabolic Syndrome No Metabolic Syndrome p Value
(N = 91) (N = 31) (N = 60) (MS vs No MS)
Clinical and biochemical features
Age (yr) 47.6 + 11.8 47 ± 14 48 ± 10 0.87
Gender (Female %) 57 39 45 0.66
BMI (kg/m2) 32.8 ± 6.8 34.3 ± 4.2 32.0 ± 7.7 0.08
BMI ≥30 (%) 42 84 53 0.008
BMI ≥35 (%) 25 39 20 0.09
Waist circumference (inches) 36.4 ± 11.2 39.5 ± 9.5 34.8 ± 11.8 0.04
Truncal obesity (%)∗ 8 13 5 0.22
Waist-hip ratio 0.9 ± 0.1 0.95 ± 0.07 0.92 ± 0.07 0.03
Systolic BP (mmHg) 129 ± 16 131.2 ± 18 128.5 ± 14.7 0.45
Diastolic BP (mmHg) 76 ± 10 76.7 ± 9.5 75.9 ± 10.4 0.70
BP ≥135/85 (%) 32 42 27 0.21
Total cholesterol (mg/dL) 203.9 ± 47.7 213.7 ± 56.6 198.81 ± 41.8 0.20
LDL cholesterol (mg/dL) 115 + 41 120 + 46 113 + 39 0.45
HDL cholesterol (mg/dL) 50 ± 15 41.7 ± 11.3 54.5 ± 15.0 0.0094
HDL ≤50 (%) 52 77 38 0.002
Fasting TG (mg/dL) 192.1 ± 182.4 273.6 ± 262.1 149.3 ± 100.6 0.016
TG ≥150 (%) 71 84 32 < 0.0001
Fasting insulin (μU/mL) 20.29 ± 11.28 24.7 ± 9.1 17.6 ± 11.3 0.002
Fasting glucose (mg/dL) 101 ± 24.7 106.1 ± 0.3 98.4 ± 25.0 0.16
Glucose ≥110 (%) 19 29 13 0.12
HOMA index 5.2 ± 3.6 6.7 ± 3.5 4.4 ± 3.5 0.005
ALT (IU/dL) 78.2 ± 51.5 79.2 ± 51.8 77.7 ± 51.8 0.90
AST (IU/dL) 54 ± 36 59.9 ± 37.4 50.72 + 35.1 0.26
Hx of DM (%) 19 29 13 0.12
Hx HTN (%) 47 71 35 0.002
Hx hyperlipidemia (%) 54 65 48 0.21
Calories/day (FFQ 98) 1,866 ± 762.5 1,795 ± 722 1,903 ± 787 0.51
Physical activity (PAQ, kcal/wk) 1,325.7 ± 1,274 1,149 ± 1,109 1,417± 1,351 0.36
NAFLD histology according to NASH-Clinical
Network scoring system
Steatosis score (0–3) 1.6 ± 1.0 2.0 ± 0.8 1.37 ± 1 0.002
Lobular inflammation (0–3) 1.4 ± 0.8 1.5 ± 0.8 1.4 ± 0.8 0.70
Hepatocyte ballooning (0–2) 0.5 ± 0.5 0.6 ± 0.5 0.4 ± 0.5 0.008
NASH activity score (0–8) 3.5 ± 1.7 4.1 ± 1.4 3.1 ± 1.7 0.004
Fibrosis score (0–4) 1.5 ± 1.2 1.8 ± 1.3 1.29 ± 1.1 0.06
Global NASH score (0–12) 4.9 ± 2.2 5.9 ± 1.7 4.4 ± 2.3 0.0006
NAFLD = nonalcoholic fatty liver disease; BMI = body mass index; BP = blood pressure; LDL = low density lipoprotein; HDL = high density lipoprotein; TG = triglyceride;
HOMA = homeostasis model assessment; ALT = alanine aminotransferase; AST = aspartate aminotransferase; DM = diabetes mellitus; HTN = hypertension; FFQ = food
frequency questionnaire; PAQ = physical activity questionnaire; NASH = nonalcoholic steatohepatitis; MS = metabolic syndrome.
∗By Fishers exact test.
Biochemical and Anthropometric Differences in Patients
with High Versus Low Global NASH Score
The median global NASH score was 5. When patients with
low and high global NASH score (0–5 vs 6–12) were com-
pared, the group with higher global NASH score had a greater
proportion of patients with obesity (BMI >30) and metabolic
syndrome, higher levels of fasting insulin, HOMA index,
serum AST levels, and less physical activity (p = 0.01−
0.001) (Table 2).
The Effect of Diet Composition and Physical Activity
Was Further Assessed
Factors associated with NASH severity (high vs low global
NASH score) were analyzed by univariable, followed by mul-
tivariable, regression models. In univariable analysis, factors
associated with a low global NASH score were male gender
and physical activity (kcal/wk) and those associated with high
global NASH score were IR (HOMA index) and the presence
of metabolic syndrome. In multivariable analysis, the pres-
ence of metabolic syndrome was significantly associated with
high global NASH score after adjusting for all other signifi-
cant factors (OR 3.48, 95% CI 1.22–9.85, p = 0.019). Factors
other than metabolic syndrome that were independently as-
sociated with a NASH severity included female gender (OR
0.28, 95% CI 0.09–0.9, p = 0.035) and HOMA index (OR
1.27, 95% CI 1.05–1.54, p = 0.014).
Alcohol Consumption
Neither current or lifetime alcohol consumption was related
to histologic severity of NAFLD (data not shown). In addi-
tion, there was no difference in alcohol consumption between
patients with and without metabolic syndrome.
DISCUSSION
This study compares the dietary intake, physical activity, and
liver histology in patients with and without metabolic syn-
drome. The prevalence of metabolic syndrome in our patients
Metabolic Syndrome in Patients with NAFLD 2251
Table 2. Comparison of Patients with High versus Low Global NASH Score
Global NASH 0–5 Global NASH 6–12
(N = 56) (N = 35) p Value
Age (yr) 48 ± 11 47 ± 13 0.92
Gender (female %) 48 29 0.05
BMI (kg/m2) 32 ± 8 34 ± 5 0.08
BMI ≥30 (%)∗ 52 83 0.006
BMI ≥35 (%) 25 37 0.32
Waist circumference (inches) 35.5 ± 11.3 39 ± 10.9 0.20
Truncal obesity (%)∗ 36 49 0.65
Waist-hip ratio 0.93 ± 0.07 0.94 ± 0.08 0.67
Systolic BP (mmHg) 129 ± 17 130 ± 14 0.78
Diastolic BP (mmHg) 76 ± 9 76 ± 12 0.82
BP ≥135/85(%) 23 43 0.08
Total cholesterol (mg/dL) 201 ± 45 208 ± 53 0.49
HDL cholesterol (mg/dL) 60 ± 57 47 ± 16 0.14
HDL ≤50 (%) 54 66 0.36
Fasting TG (mg/dL) 167 ± 107 231 ± 257 0.17
TG ≥150 (%) 39 66 0.025
Fasting insulin (μU/dL) 17 ± 10 25 ± 12 0.001
Fasting glucose (mg/dL) 98 ± 26 105 ± 23 0.18
Glucose ≥110 (%) 13 29 0.10
Hx of DM vs no DM (%) 20 20 0.82
Hx of HTN vs no HTN (%) 9 3:32 (9) 1.00∗
Hx of hyperlipidemia (%) 56 54 0.88
HOMA index 4.3 ± 3.1 6.8 ± 3.9 0.003
Metabolic syndrome (%) 21 54 0.003
ALT (IU/dL) 97 ± 45 94 ± 66 0.05
AST (IU/dL) 46 ± 24 66 ± 47 0.03
Dietary macronutrient composition
Kilocalories/day (FFQ) 1,859 ± 805 1,877 ± 701 0.91
% Carbohydrate 46 ± 11 50 ± 11 0.14
% Fat 39 ± 9 37 ± 10 0.16
% Protein 16 ± 3 15 ± 3 0.44
Physical activity
kcal/wk (PAQ) 1,566 ± 1,429 942 ± 864 0.01
NASH = nonalcoholic steatohepatitis; BMI = body mass index; BP = blood pressure; HDL = high density lipoprotein; TG = triglyceride; Hx = history of; DM = diabetes
mellitus; HTN = hypertension; HOMA = homeostasis model assessment; ALT = alanine aminotransferase; AST = aspartate aminotransferase; FFQ = food frequency
questionnaire; PAQ = physical activity questionnaire.
∗By Fisher’s exact test.
is similar to that reported in other studies in NAFLD (36%
of NAFLD patients without diabetes) (22), which is higher
than that of the general population in the United States.
As expected, IR was significantly greater in the group with
metabolic syndrome. We found that NAFLD patients with
metabolic syndrome consumed more carbohydrates, less fat,
and equal amounts of protein and total calories, compared
with those without metabolic syndrome. Physical activity did
not differ between the two groups. When comparing histo-
logic severity of NAFLD, patients with metabolic syndrome
had higher scores for steatosis grade, NASH activity, and
global NASH severity.
Despite the increasing prevalence of NAFLD in the United
States there is no effective medical therapy available to date.
Current recommendations are to lose weight through diet and
exercise with no robust evidence to support this recommenda-
tion (23). Individuals who are physically active and consume
a low carbohydrate diet have a lower risk of having metabolic
syndrome (5, 12, 24). In addition, obese patients have im-
proved IR (25–29), abdominal obesity (25), and lower odds
for hepatic inflammation (14) with a lower carbohydrate diet.
We have recently shown that intense nutritional counseling
with dietary modification focusing on a diet improving IR
and decreasing carbohydrate consumption, results in histo-
logic improvement in NASH (30). Although a low-fat diet
has generally been recommended in patients with NAFLD,
recent studies show that a greater short-term weight loss and
improvement in markers of the metabolic syndrome is associ-
ated with a low-carbohydrate diet without significant adverse
effects (31). The role of dietary composition with a decrease
in carbohydrate relative to the total calories consumed, as well
as increased physical activity, in NAFLD histology, however,
needs to be further studied.
Patients with a higher global NASH score were more likely
to be obese, had greater IR as measured by HOMA, higher
AST, and less physical activity. Our findings are consistent
with previous studies suggesting that patients with NAFLD
and DM, which is a component of metabolic syndrome and
associated with IR, have more aggressive disease with a
higher percentage of cirrhosis and higher odds of liver cell
necrosis compared with those without diabetes (32). Patients
who have greater splanchnic (visceral) fat distribution may
be particularly prone to the effects of IR and possibly to a
more aggressive form of NASH (6, 9). This may explain the
2252 Kang et al.
Figure 1. Macronutrient composition of diet in NAFLD patients.
B versus C carbohydrate, fat, and protein p value = 0.03, 0.006, and
0.91, respectively.
more severe disease seen in our patients with metabolic syn-
drome and higher global NASH score, who had significantly
larger waist circumference (a measure of visceral adiposity)
and a greater degree of IR. When controlled for other factors,
including dietary composition and physical activity, the pres-
ence of metabolic syndrome appeared to be one of the most
significant risk factors for global NASH severity in addition
to HOMA index and female gender.
The time of NAFLD diagnosis to enrollment in the study
was less than 4 wk. Physical activity and dietary informa-
tion obtained was an average over the past year; therefore,
the information obtained for dietary food consumption and
physical activity was likely a good reflection of the patient’s
dietary and exercise habits prior to the diagnosis of NAFLD.
Our study does have limitations. Patients with ALT <1.5
times the upper limit of normal were excluded if they did not
have radiologic imaging with features of steatosis, thus the
patients enrolled do not represent all patients with NAFLD.
The size of the study was not large, all patients were from a
single institution, and NAFLD histologic severity was limited
to a mean global NASH score of 4.9 ± 2.2 and did not rep-
resent the entire spectrum of NAFLD. The lack of a control
group does not allow us to establish an absolute modification
of dietary habits on histologic severity.
Dietary and physical activity information was obtained
through self-reported questionnaires, which may be subject
to underreporting and recall bias. The dietary questionnaire
assessed the dietary intake of diverse food groups and snacks
based on a typical American diet. The majority of the pa-
tients in our study were Caucasian Americans and based on
the dietician interviews, this questionnaire was appropriate in
capturing their usual dietary intake. The dietary questionnaire
was able to capture information regarding saturated, monoun-
saturated, and polyunsaturated fat but we were not able to ob-
tain trans fat consumption, which may affect IR and NAFLD
histology. Though it has been shown that a carbohydrate-rich
diet, especially with a high glycemic index, worsens IR (26),
the FFQ 98 does not assess the glycemic index of carbohy-
drates.
The PAQ is a reflection of leisurely activities, blocks
walked, and flights of stairs climbed. Many of the physical
activities noted by homemakers are from household activi-
ties that this questionnaire does not address. With the com-
pendium of physical activities (33) that facilitates coding of
physical activities, we are able to better estimate the MET
used for each activity and this may be a better estimate of
activity in the future.
In conclusion, we have shown that those with metabolic
syndrome and NAFLD have greater histologic severity of
their underlying liver disease than patients without metabolic
syndrome. In addition, patients with metabolic syndrome and
NAFLD also consume more carbohydrates and less fat com-
pared with those without metabolic syndrome. Further stud-
ies of a larger number of NAFLD patients with a broad spec-
trum of histologic severity will be needed to determine the
effect of dietary modification such as carbohydrate restriction
on histologic improvement of NAFLD.
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STUDY HIGHLIGHTS
What Is Current Knowledge Nonalcoholic fatty liver disease (NAFLD) is a mani-
festation of metabolic syndrome. A diet with fewer carbohydrates and exercise improves
metabolic syndrome. NAFLD patients with metabolic syndrome consume a
diet with fewer carbohydrates and more fat compared
to NAFLD patients without metabolic syndrome. NAFLD patients with metabolic syndrome have more
severe histologic findings of NAFLD compared to
those without metabolic syndrome.
What Is New Here We have shown that there may be a role for a diet with
fewer carbohydrates and moderate fat consumption in
improving NAFLD histology in patients with NAFLD
and metabolic syndrome.
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